You have free access to this content

Cancer

Cover image for Cancer

1 July 2008

Volume 113, Issue 1

Pages 1–224

  1. Cancer Scope

    1. Top of page
    2. Cancer Scope
    3. Editor's Note
    4. Review Article
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      Cancer scope (pages 1–3)

      Carrie Printz

      Version of Record online: 19 JUN 2008 | DOI: 10.1002/cncr.23754

  2. Editor's Note

    1. Top of page
    2. Cancer Scope
    3. Editor's Note
    4. Review Article
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      New content highlighted for Cancer (page 4)

      Raphael E. Pollock

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23565

  3. Review Article

    1. Top of page
    2. Cancer Scope
    3. Editor's Note
    4. Review Article
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      Bronchopulmonary neuroendocrine tumors (pages 5–21)

      Bjorn I. Gustafsson, Mark Kidd, Anthony Chan, Max V. Malfertheiner and Irvin M. Modlin

      Version of Record online: 12 MAY 2008 | DOI: 10.1002/cncr.23542

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise ≈20% of all lung cancers. BP-NETs include 4 histologic subgroups: typical carcinoid tumor, atypical carcinoid tumor, large-cell neuroendocrine carcinoma, and small-cell lung carcinoma. The review assesses their current classification and management with a focus on the features of each subgroup, emphasizing their specific diagnostic and therapeutic options.

  4. Original Articles

    1. Top of page
    2. Cancer Scope
    3. Editor's Note
    4. Review Article
    5. Original Articles
    6. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Completion of adjuvant radiation therapy among women with breast cancer (pages 22–29)

      Tomasz P. Srokowski, Shenying Fang, Zhigang Duan, Thomas A. Buchholz, Gabriel N. Hortobagyi, James S. Goodwin and Sharon H. Giordano

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23513

      • original image

      Few studies have evaluated adherence to radiotherapy outside the context of a clinical trial; 24,510 women were studied to determine rates of radiotherapy completion. Overall, 87% completed radiation, but women who were black, had a mastectomy, or were hospitalized during treatment were less likely to complete adjuvant radiation.

    2. You have free access to this content
      How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? (pages 30–37)

      Min Yi, Funda Meric-Bernstam, Merrick I. Ross, Jeri S. Akins, Rosa F. Hwang, Anthony Lucci, Henry M. Kuerer, Gildy V. Babiera, Michael Z. Gilcrease and Kelly K. Hunt

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23514

      In general, the removal of a maximum of 5 sentinel lymph nodes (SLNs) at surgery allows for recovery of >99% of positive SLNs in patients with breast cancer. Tumor histology, patient race, and tumor size and location may influence this number.

    3. You have free access to this content
      Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy : Analysis of the NCI Surveillance, Epidemiology, and End Results database (pages 38–47)

      James B. Yu, Lynn D. Wilson, Tina Dasgupta, William A. Castrucci and Joanne B. Weidhaas

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23512

      • original image
      • original image

      This National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database study shows that postoperative radiation therapy does not appear to improve overall survival for T3N0 breast cancer after modified radical mastectomy. The study does identify higher-risk subsets of patients that may benefit from postoperative radiation in terms of local control, which could not be studied in SEER.

    4. Endocrine Disease
      You have free access to this content
      Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma (pages 48–56)

      Michael Rivera, Ronald A. Ghossein, Heiko Schoder, Daniel Gomez, Steven M. Larson and R. Michael Tuttle

      Version of Record online: 16 MAY 2008 | DOI: 10.1002/cncr.23515

      • original image
      • original image
      • original image

      Radioactive iodine-refractory (RAIR), 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) positive thyroid carcinomas represent the major cause of deaths from thyroid carcinoma and as such is the main focus of novel target therapies. In the current study, the authors describe the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma.

    5. Gastrointestinal Disease
      You have free access to this content
      Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation (pages 57–64)

      Hak-Mien Quah, Joanne F. Chou, Mithat Gonen, Jinru Shia, Deborah Schrag, Leonard B. Saltz, Karyn A. Goodman, Bruce D. Minsky, W. Douglas Wong and Martin R. Weiser

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23516

      • original image
      • original image

      Preoperative chemoradiation is the standard treatment for locally advanced rectal cancer, and tumor response to preoperative therapy is a strong predictor of disease-free survival. However, outcome is most accurately estimated based on final pathologic stage.

    6. Genitourinary Disease
      You have free access to this content
      Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy (pages 65–71)

      Luca Cindolo, Paolo Chiodini, Ciro Gallo, Vincenzo Ficarra, Luigi Schips, Jacques Tostain, Alexandre de La Taille, Walter Artibani and Jean Jacques Patard

      Version of Record online: 12 MAY 2008 | DOI: 10.1002/cncr.23517

      • original image
      • original image
      • original image

      The University of California at Los Angeles (UCLA) Integrated Staging System (UISS) prognostic model has good discrimination accuracy. It is possible to improve its prediction accuracy in European patients by a recalibration procedure.

    7. You have free access to this content
      Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma (pages 72–77)

      Eric Jonasch, Walter M. Stadler, Ronald M. Bukowski, Teresa G. Hayes, Atul Varadhachary, Rajesh Malik, Robert A. Figlin and Sandy Srinivas

      Version of Record online: 16 MAY 2008 | DOI: 10.1002/cncr.23519

      A phase 2 study using talactoferrin, an oral immunomodulatory agent, met its progression-free survival endpoint in a 44-patient trial of patients with metastatic renal cell carcinoma. Randomized studies are warranted to further investigate this compound.

    8. You have free access to this content
      Renal cell cancer stage migration : Analysis of the National Cancer Data Base (pages 78–83)

      Christopher J. Kane, Katherine Mallin, Jamie Ritchey, Matthew R. Cooperberg and Peter R. Carroll

      Version of Record online: 19 MAY 2008 | DOI: 10.1002/cncr.23518

      • original image
      • original image
      • original image

      There is stage migration toward earlier stages of disease for kidney cancer patients in the National Cancer Data Base. There is improved survival for more recently diagnosed patients with kidney cancer.

    9. You have free access to this content
      Survival rates after resection for localized kidney cancer: 1989 to 2004 (pages 84–96)

      Paul Russo, Thomas L. Jang, Joseph A. Pettus, William C. Huang, Scott E. Eggener, Matthew F. O'Brien, Michael E. Karellas, Nicholas T. Karanikolas and Megan A. Kagiwada

      Version of Record online: 9 MAY 2008 | DOI: 10.1002/cncr.23520

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      In this study of 1618 patients with localized kidney cancer who underwent nephrectomy between 1989 and 2004, trends in 5-year progression-free survival and overall survival did not improve or differ significantly over time despite an increasing number of nephrectomies and a size migration toward smaller tumors. These findings argue for a re-evaluation of the current treatment paradigm of surgically removing solid renal masses on initial detection and consideration of active surveillance for patients with select renal tumors.

    10. Head and Neck Disease
      You have free access to this content
      Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma : Predictive and prognostic correlation (pages 97–107)

      Susan Muller, Ling Su, Mourad Tighiouart, Nabil Saba, Hongzheng Zhang, Dong M. Shin and Zhuo (Georgia) Chen

      Version of Record online: 12 MAY 2008 | DOI: 10.1002/cncr.23557

      • original image
      • original image
      • original image
      • original image

      By analyzing the tissue specimens and cell lines of squamous cell carcinoma of the head and neck, the results from this study illustrated that examining not only the expression but also the localization of epidermal growth factor receptor (EGFR) and E-cadherin simultaneously may have clinical relevance in predicting lymph node metastasis, patient survival, and response to EGFR-targeted therapy.

    11. Hematologic Malignancies
      You have free access to this content
      Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group (pages 108–116)

      David J. Inwards, Paul A. S. Fishkin, David W. Hillman, David W. Brown, Stephen M. Ansell, Paul J. Kurtin, Rafael Fonseca, Roscoe F. Morton, Michael H. Veeder and Thomas E. Witzig

      Version of Record online: 9 MAY 2008 | DOI: 10.1002/cncr.23537

      • original image
      • original image

      In this study, the authors established that cladribine has substantial single-agent activity in both recurrent and untreated mantle cell lymphoma and may be administered safely to elderly patients. The results also indicated that the addition of rituximab to cladribine may increase the duration of response.

    12. You have free access to this content
      High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma : Comparison of results in human immunodeficiency virus-infected and noninfected patients (pages 117–125)

      Albert Oriol, Josep-Maria Ribera, Juan Bergua, Eduardo Giménez Mesa, Carlos Grande, Jordi Esteve, Salut Brunet, Maria-Jose Moreno, Lourdes Escoda, Jesus-Maria Hernandez-Rivas and Dieter Hoelzer

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23522

      • original image
      • original image
      • original image

      Despite a higher incidence of severe mucositis and infections, the outcome of HIV-infected patients with Burkitt lymphoma/leukemia is comparable to that observed in HIV-negative patients in terms of complete remission rates and survival.

    13. Hepatobiliary Disease
      You have free access to this content
      Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms (pages 126–134)

      Clifford S. Cho, Daniel M. Labow, Laura Tang, David S. Klimstra, Agnes G. Loeffler, Glen E. Leverson, Yuman Fong, William R. Jarnagin, Michael I. D'Angelica, Sharon M. Weber, Leslie H. Blumgart and Ronald P. DeMatteo

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23523

      • original image
      • original image

      A novel, 3-tier, pathologic grading system (low, intermediate, and high grade) based on mitotic activity and histologic necrosis permitted stratification of expected overall, progression-free, and symptom-free survival for patients who underwent surgical resection of hepatic neuroendocrine neoplasms.

    14. Lung Disease
      You have free access to this content
      Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions (pages 135–142)

      Wendy A. Cooper, Maija R.J. Kohonen-Corish, Liqing Zhuang, Brian McCaughan, Catherine Kennedy, Gavin Screaton, Robert L. Sutherland and C-Soon Lee

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23528

      • original image
      • original image

      The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor, DR5, mediates proapoptotic signals and immunohistochemistry was used to show it is expressed at significantly higher levels in early-stage nonsmall-cell lung cancer (NSCLC) and precursor lesions compared with normal bronchial epithelium. High expression of DR5 correlated with poorly differentiated tumors and poor overall survival in univariate survival analysis, and in multivariate analysis was an independent predictor of shorter disease-free survival among smokers but was not an independent prognostic marker among the entire cohort of NSCLC.

    15. You have free access to this content
      Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : Result of a randomized pilot study (pages 143–149)

      Dae Ho Lee, Ji-Youn Han, Heung Tae Kim, Sung Jin Yoon, Hong Ryull Pyo, Kwan Ho Cho, Sang-Hoon Shin, Heon Yoo, Seung-Hoon Lee and Jin Soo Lee

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23526

      • original image
      • original image

      The current randomized pilot trial investigated whether primary chemotherapy was feasible in terms of efficacy, survival, toxicity profile, and quality of life compared with whole-brain radiotherapy given first in chemotherapy-naive patients nonsmall cell lung cancer who have synchronous brain metastasis. The results indicate that primary chemotherapy is more feasible and can be an appropriate option for patients with synchronous brain metastasis when neurologic symptoms or signs are absent or controlled. The role and timing of whole-brain radiotherapy should be defined in further studies in this clinical setting.

    16. You have free access to this content
      Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers : A meta-analysis and evaluation of national brands (pages 150–157)

      Tawee Tanvetyanon and Gerold Bepler

      Version of Record online: 21 APR 2008 | DOI: 10.1002/cncr.23527

      • original image
      • original image
      • original image

      This meta-analysis, based on data from 109,394 subjects, conclusively demonstrated a 24% increase in the risk of lung cancer among smokers who received high-dose beta-carotene supplements. Beta-carotene is prevalent in national brand multivitamins and high-dose beta-carotene is found among multivitamin brands retailed to improve vision.

    17. Neuro-Oncology
      You have free access to this content
      Multidisciplinary management of colorectal brain metastases : A retrospective study (pages 158–165)

      Tim J. Kruser, Samuel T. Chao, Paul Elson, Gene H. Barnett, Michael A. Vogelbaum, Lilyana Angelov, Robert J. Weil, Robert Pelley and John H. Suh

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23531

      • original image

      The authors report on the management and outcomes of 49 patients at a single institution who had a total of 102 brain metastases from colorectal cancer. Survival after central nervous system (CNS) involvement was poor (5.1 months), and the results indicted that late development of CNS involvement (>1 year after primary diagnosis) may predict for poorer survival after therapy for colorectal cancer brain metastases.

    18. You have free access to this content
      Retinoblastoma (Rb) tumor-suppressor pathway alterations in meningeal hemangiopericytomas: High E2F transcription factor 1 expression and loss of Rb expression : Study by double immunofluorescence staining and laser-scanning confocal microscopy (pages 166–174)

      Juan-Carlos Martinez, Julio-Cesar Palomino, Rafael Samaniego, Juan M. Sepulveda, Ana Cabello and Jose R. Ricoy

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23532

      • original image
      • original image
      • original image

      Alterations in the retinoblastoma (Rb) pathway were analyzed in 18 specimens of meningeal hemangiopericytoma (MHPC). The loss of Rb expression, loss of cyclin-dependent kinase 4 inhibitor p16/INKa expression, and high E2F1 expression indicated impairment of the Rb suppressor pathway. In addition, the colocalization of human mouse double-minute 2 with E2F1 and Rb indicated that inactivation of the Rb suppressor pathway and transactivation of DNA synthesis genes may play a pathogenic role in MHPC.

    19. You have free access to this content
      Supratentorial ependymomas: Prognostic factors and outcome analysis in a retrospective series of 46 adult patients (pages 175–185)

      Philippe Metellus, Dominique Figarella-Branger, Jacques Guyotat, Marylin Barrie, Roch Giorgi, Anne Jouvet, Olivier Chinot and for the Club de Neuro-Oncologie de la Société Française de Neurochirurgie and the Association des Neuro-Oncologues d'Expression Française

      Version of Record online: 9 MAY 2008 | DOI: 10.1002/cncr.23530

      • original image
      • original image

      The authors studied a series of adult patients with supratentorial ependymomas to characterize the roles of surgery and histology in tumor control. In association with age and extent of surgery, histologic grade was identified as a major prognostic factor in adults with supratentorial ependymomas.

    20. Discipline

      Clinical Trials
      You have free access to this content
      Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck (pages 186–192)

      Jill Gilbert, Anthony Cmelak, Yu Shyr, James Netterville, Brian B. Burkey, Robert J. Sinard, Wendall G. Yarbrough, Christine H. Chung, Joseph M. Aulino and Barbara A. Murphy

      Version of Record online: 16 MAY 2008 | DOI: 10.1002/cncr.23545

      • original image
      • original image

      The combination of irinotecan and cisplatin is an active regimen in metastatic or recurrent squamous cell carcinoma of the head and neck. However, this combination of drugs is associated with significant toxicities.

    21. Medical Oncology
      You have free access to this content
      Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid (pages 193–201)

      Allan Lipton, Richard Cook, Fred Saad, Pierre Major, Patrick Garnero, Evangelos Terpos, Janet E. Brown and Robert E. Coleman

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23529

      • original image
      • original image

      Normalization of elevated N-telopeptide of type I collagen (NTX) levels is associated with improved survival in patients with bone metastases from solid tumors. Zoledronic acid normalized NTX in the majority of patients with elevated baseline NTX, and there was a continuum of survival benefits corresponding with NTX decreases relative to baseline even in the absence of a transition from an elevated to a normal NTX state.

    22. Disease Site

      Pediatric Oncology
      You have free access to this content
      Preoperative Wilms tumor rupture : A retrospective study of 57 patients (pages 202–213)

      Hervé J. Brisse, Gudrun Schleiermacher, Sabine Sarnacki, Sylvie Helfre, Pascale Philippe-Chomette, Liliane Boccon-Gibod, Michel Peuchmaur, Véronique Mosseri, Yves Aigrain and Sylvia Neuenschwander

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23535

      • original image
      • original image
      • original image
      • original image
      • original image

      Computed tomography scan at diagnosis in patients with Wilms tumor demonstrates signs of tumor rupture in approximately 25% of all patients. In this study, the authors demonstrated that imaging can distinguish rare intraperitoneal ruptures associated with a high risk of peritoneal disease recurrence from frequent retroperitoneal-only ruptures that can be treated according to the final pathologic stage without systematic upstaging.

    23. Discipline

      Symptom Control and Palliative Care
      You have free access to this content
      Effect of exercise on upper extremity pain and dysfunction in head and neck cancer survivors : A randomized controlled trial (pages 214–222)

      Margaret L. McNeely, Matthew B. Parliament, Hadi Seikaly, Naresh Jha, David J. Magee, Mark J. Haykowsky and Kerry S. Courneya

      Version of Record online: 5 MAY 2008 | DOI: 10.1002/cncr.23536

      • original image
      • original image
      • original image

      A 12-week progressive resistance exercise program resulted in significant improvements in shoulder pain, disability, and upper extremity muscular strength and endurance in 52 head and neck cancer survivors who presented with postsurgical shoulder pain and dysfunction.

  5. Correspondence

    1. Top of page
    2. Cancer Scope
    3. Editor's Note
    4. Review Article
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients (pages 223–224)

      Miriam Lopez Gomez, Cesar Gomez-Raposo and Francisco Lobo Samper

      Version of Record online: 28 APR 2008 | DOI: 10.1002/cncr.23524

      Corrected by:

      Erratum: Erratum

      Vol. 115, Issue 9, 2022, Version of Record online: 11 MAR 2009

    2. You have free access to this content

SEARCH

SEARCH BY CITATION